Clinical Trials Logo

Pyoderma Gangrenosum clinical trials

View clinical trials related to Pyoderma Gangrenosum.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04895566 Completed - Clinical trials for Pyoderma Gangrenosum

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Start date: May 24, 2021
Phase: Early Phase 1
Study type: Interventional

Phase 0/1 local application of the monoclonal antibody (Mab) sB24M in patients with purulent pyoderma (chronic ulcerative pyoderma) by injection into the affected areas. Monoclonal antibody (Mab) sB24 negatively regulates immune-inflammatory processes through CD47 / TNF-α Axis promotes epithelialization of damaged tissue.

NCT ID: NCT03971643 Completed - Clinical trials for Pyoderma Gangrenosum

Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum

Start date: May 16, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.

NCT ID: NCT03311464 Completed - Clinical trials for Pyoderma Gangrenosum

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Start date: October 27, 2017
Phase: Phase 3
Study type: Interventional

This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).

NCT ID: NCT03137160 Completed - Clinical trials for Pyoderma Gangrenosum

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Start date: May 4, 2017
Phase: Phase 2
Study type: Interventional

An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

NCT ID: NCT02733094 Completed - Clinical trials for Pyoderma Gangrenosum

Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Start date: April 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17 therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration until week 16) for the treatment of pyoderma gangrenosum.

NCT ID: NCT01965613 Completed - Clinical trials for Pyoderma Gangrenosum

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Start date: January 31, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

NCT ID: NCT01882504 Completed - Clinical trials for Pyoderma Gangrenosum

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.

NCT ID: NCT01302795 Completed - Clinical trials for Pyoderma Gangrenosum

Canakinumab for Pyoderma Gangrenosum

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.

NCT ID: NCT00791557 Completed - Ulcerative Colitis Clinical Trials

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Start date: October 2008
Phase: N/A
Study type: Interventional

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.